07:37 AM EST, 11/20/2025 (MT Newswires) -- Moderna ( MRNA ) said Thursday, ahead of its analyst day later that day, that it expects up to 10% revenue growth next year.

Chief executive officer Stephane Bancel said the company will reduce its research & develop investments and "diversify further into oncology.

The company said it is reducing its 2026 and 2027 expected cash costs to around $4.2 billion and a range of between $3.5 billion and $3.9 billion, respectively, improving gross margins by more than 10% over the next three years.

The company said it expects to expand seasonal vaccine franchise from three to up to six approved products by 2028.